Conditional V2 Vasopressin Receptor Mutant Mice as a Model to Study X-linked Nephrogenic Diabetes Insipidus (XNDI)
X-linked nephrogenic diabetes insipidus (XNDI) is a severe kidney disease caused by inactivating mutations in the V2 vasopressin receptor (V2R) gene that result in the loss of renal urine-concentrating ability. At present, no specific pharmacological therapy has been developed for XNDI, primarily due to the lack of suitable animal models. This technology provides a unique and viable animal model of XNDI. NIH investigators have generated mice in which the V2R gene could be conditionally deleted during adulthood by administration of 4-OH-tamoxifen. Radioligand-binding studies confirmed the lack of V2R-binding sites in kidney...
Source: NIH OTT Licensing Opportunities - March 24, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Synthetic Bacterial Nanoparticles as Drug and Vaccine Delivery Vehicles
Bacterial spores can be modified to display molecules of interest, including drugs, immunogenic peptides, antibodies and other functional proteins of interest (such as enzymes).   The resulting engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants.Researchers at the National Cancer Institute ’s (NCI) Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of the...
Source: NIH OTT Licensing Opportunities - March 23, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Nanoparticle Platform Using Bacterial Spore Coat Proteins
Bacterial spores can be modified to display molecules of interest, including drugs, immunogenic peptides, antibodies and other functional proteins of interest (such as enzymes).   The resulting engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants.Researchers at the National Cancer Institute ’sLaboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions...
Source: NIH OTT Licensing Opportunities - March 23, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Nanoparticle Display Platform Using Bacterial Spore Coat Proteins for Use in Treatment of Infections, as an Adjuvant for the Delivery of Vaccines, or the Enzymatic Degradation of Environmental Pollutants
Bacterial spores can be modified to display molecules of interest, including drugs, immunogenic peptides, antibodies and other functional proteins of interest (such as enzymes). The resulting engineered bacterial spores can provide many useful functions such as the treatment of infections, use as an adjuvant for the delivery of vaccines, and the enzymatic degradation of environmental pollutants.Researchers at the National Cancer Institute ’s Laboratory of Molecular Biology have developed a novel, synthetic spore husk-encased lipid bilayer (SSHEL) particle that is uniquely suited for a variety of these functions.The a...
Source: NIH OTT Licensing Opportunities - March 23, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

N6, A Novel, Broad, Highly Potent HIV-specific Antibody
This is a new antibody coming out of NIAID ’s intramural program. N6 has evolved a unique mode of binding that depends less on a variable area of the HIV envelope known as the V5 region and focuses more on conserved regions, which change relatively little among HIV strains. This allows N6 to tolerate changes in the HIV envelope, including the attachment of sugars in the V5 region, a major mechanism by which HIV develops resistance to other VRC01-class antibodies. N6 was shown in pre-clinical studies to neutralize 98 percent of HIV isolates tested. The studies also demonstrate that N6 neutralizes 80 percent of HIV iso...
Source: NIH OTT Licensing Opportunities - March 15, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Simple and Rapid Assay to Detect Acute Subtype B and Group M HIV-1 Infections
Within recent years, point-of-care (POC) testing has allowed for many individuals to be screened for and provided with HIV test results. It is critical to be able to accurately detect acute HIV infections as this is a stage where the risk of transmission is great. Additionally, early HIV detection could lead to less high-risk behavior, thereby reducing transmission. Currently, there are no rapid, cost-effective diagnostic tests sensitive enough to detect acute HIV-1 infections for the POC setting.Researchers at the CDC have developed an HIV-1 detection assay using reverse-transcription loop-mediated isothermal amplificatio...
Source: NIH OTT Licensing Opportunities - March 15, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

AMA1-RON2 Complex-Based Vaccine Against Malaria
This technology relates to a malaria vaccine composed of a protein complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 (RON2) with an adjuvant. AMA1 is a crucial component of thePlasmodium invasion machinery and is a leading candidate for antimalarial vaccine development. AMA1-based vaccines have shown ability to block red cell invasion inin vitro assays, but protection has so far not translated toin vivo human infections. NIAID investigators have demonstrated that interaction between AMA1 and RON2 (or peptide thereof) is essential for malaria parasites to successfully enter human red blood cells (RBCs). V...
Source: NIH OTT Licensing Opportunities - March 9, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

New T-cell Immunotherapy That Targets Aggressive Epithelial Tumors
Metastatic cancers are the cause of up to 90% of cancer deaths, yet few treatment options exist for patients with metastatic disease. Adoptive transfer of T cells that express tumor-reactive T-cell receptors (TCRs) has been shown to mediate regression of metastatic cancers in some patients. Unfortunately, identification of antigens that are expressed solely by cancer cells and not normal tissues has been a major challenge for the development of T-cell based immunotherapies. Thus, it is essential to find novel target antigens that are differentially expressed in cancer versus normal tissues.Researchers at the National Cance...
Source: NIH OTT Licensing Opportunities - March 3, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

A New Class of Stable Heptamethine Cyanine Fluorophores and Biomedical Applications Thereof
Heptamethine cyanines are among the most widely used near-IR fluorophores. The near-IR range (between about 650 nm and 900 nm) is very useful for imaging applications due to the absence of background autofluorescence. Despite extensive use, many of these fluorophores suffer from chemical instability. Specifically, most of the current and commonly used fluorophores undergo a phenoxy to thiol exchange reaction in the presence of primary thiols. This exchange reaction is problematic during conjugation reactions of cysteine containing macromolecules. These exchange reactions are further complicated by the fact that they occur ...
Source: NIH OTT Licensing Opportunities - March 2, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Stable Fluorophores for Optical-Guided Imaging in Surgical Interventions
Researchers in the NCI Chemical Biology Laboratory developed an improved class of heptamethine cyanines fluorophore dyes useful for imaging applications in the near-IR range (750-850 nm). A new chemical reaction provides easy access to novel molecules with improved properties. Specifically, these dyes display greater resistance to thiol nucleophiles, and are more robust while maintaining excellent optical properties.These new dyes have been successfully employed in variousin vivo imaging applications andin vitro labeling and microscopy applications. The NCI inventors continue to develop these dyes as targetable agents for ...
Source: NIH OTT Licensing Opportunities - March 2, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

CD300b Expression Exacerbates Endotoxemia and Septic Peritonitis
The innate immune system is the first line of host defense against invading pathogens. Lipopolysaccharides (LPS), present in gram-negative bacteria membranes, cause strong immune responses following detection by the Toll-like receptor 4 (TLR4) on immune cells. This detection results in the release of pro-inflammatory cytokines, such as tumor necrosis factor alpha, interleukin-6, and interferon gamma, to assist with clearance of the infectious insult. In parallel, interleukin-10 (IL-10), an anti-inflammatory cytokine, is induced to limit the immune response. This is because unchecked immune activation leads to a more severe...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Inhibition of Host Heme Oxygenase-1 as an Adjunctive Treatment to Improve the Outcome of Conventional Antibiotic Chemotherapy of Mycobacterium tuberculosis (Mtb) Infection
This invention describes the adjunctive use of heme oxygenase-1 (HO-1) inhibitors to improve the outcome of conventional antibiotic treatment for tuberculosis. The existent standard of care requires prolonged administration of drug. Due to the long duration of treatment, methods that can more rapidly control tuberculosis in patients are clearly needed.NIAID researchers have discovered that inhibition of host HO-1 reducesMycobacterium tuberculosis (Mtb) growth in vivo and, more importantly, when used as an adjunct to conventional chemotherapy, results in a marked improvement in pulmonary bacterial control. In particular, it...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

CD300b Expression Exacerbates Endotoxemia and Septic Peritonitis
The innate immune system is the first line of host defense against invading pathogens. Lipopolysaccharides (LPS), present in gram-negative bacteria membranes, cause strong immune responses following detection by the Toll-like receptor 4 (TLR4) on immune cells. This detection results in the release of pro-inflammatory cytokines, such as tumor necrosis factor alpha, interleukin-6, and interferon gamma, to assist with clearance of the infectious insult. In parallel, interleukin-10 (IL-10), an anti-inflammatory cytokine, is induced to limit the immune response. This is because unchecked immune activation leads to a more severe...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Inhibition of Host Heme Oxygenase-1 as an Adjunctive Treatment to Improve the Outcome of Conventional Antibiotic Chemotherapy of Mycobacterium tuberculosis (Mtb) Infection
This invention describes the adjunctive use of heme oxygenase-1 (HO-1) inhibitors to improve the outcome of conventional antibiotic treatment for tuberculosis. The existent standard of care requires prolonged administration of drug. Due to the long duration of treatment, methods that can more rapidly control tuberculosis in patients are clearly needed.NIAID researchers have discovered that inhibition of host HO-1 reducesMycobacterium tuberculosis (Mtb) growth in vivo and, more importantly, when used as an adjunct to conventional chemotherapy, results in a marked improvement in pulmonary bacterial control. In particular, it...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Synergistic Internal Ribosomal Entry Site (IRES) —MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development
Many members of theFlaviviridae family are emerging and reemerging human pathogens that have caused outbreaks of devastating and often fatal diseases and represent a serious public health problem on a global scale. There is no single attenuation strategy that exists which is sufficient to prepare a safe, efficacious and immunogenic live attenuated virus vaccine that will work universally forFlaviviridae. This patent application claims live attenuated flavivirus vaccines, live attenuated multivalent flavivirus vaccines, and methods of preventing flavivirus infections as well as methods of making the vaccines claimed in the ...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

A Bivalent Conjugate Vaccine for Malaria and Typhoid Prophylaxis
Malaria is the single leading cause of mortality, especially among children in the developing world. Typhoid fever, caused by infection withSalmonella typhi, is known to be endemic with malaria and causes its own significant disease burden. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed a novel bivalent vaccine candidate that may effectively prevent malaria and typhoid. This approach significantly enhances immune response to the Pfs25 Malaria transmission blocking antigen and produces a robust immune response againstSalmonella typhi...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Single-Chain Antibodies Directed to Norovirus GI.1 and GII.4 and Their Use
Vaccines and therapies to prevent and treat Norovirus infections are not available, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group settings, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks. This application claims isolated VHH monoclonal antibodies that specifically bind to a Norovirus polypeptide. Llama-derived single chain antibody fragments (also called VHH) are small, recombinant monoclonal antibodies of 15 kDa ( “nanobodies”) with several advantages over conventional an...
Source: NIH OTT Licensing Opportunities - March 1, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Zika Virus Vaccines
Zika virus (ZIKV) is a flavivirus transmitted by mosquitos that is strongly linked to neurological complications including Guillain-Barr é syndrome, meningoencephalitis, and microcephaly. The association between active ZIKV infection during pregnancy and microcephaly and intrauterine growth retardation in the fetus has been confirmed in murine models of ZIKV infection.Scientists at NIAID have developed nucleic acid-based vaccine candidates to prevent ZIKV infection in humans. The current lead candidate vaccine is a plasmid DNA vaccine demonstrated to accord protection in preclinical models and is undergoing clinical...
Source: NIH OTT Licensing Opportunities - February 28, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Zika Virus Vaccines
Zika virus (ZIKV) is a flavivirus transmitted by mosquitos that is strongly linked to neurological complications including Guillain-Barr é syndrome, meningoencephalitis, and microcephaly. The association between active ZIKV infection during pregnancy and microcephaly and intrauterine growth retardation in the fetus has been confirmed in murine models of ZIKV infection.Scientists at NIAID have developed nucleic acid-based vaccine candidates to prevent ZIKV infection in humans. The current lead candidate vaccine is a plasmid DNA vaccine demonstrated to accord protection in preclinical models and is undergoing clinical...
Source: NIH OTT Licensing Opportunities - February 28, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

A Human Progenitor Mast Cell Line for Allergic and Fibrotic Research and Therapeutic Screening
Hermansky-Pudlak Syndrome type-1 (HPS-1) is a rare genetic disorder that affects around 1 in 500,000 people worldwide and 1 in 1,800 Puerto Ricans. Patients with HPS-1 display oculocutaneous albinism, bleeding due to platelet abnormality, and pulmonary fibrosis. Those that develop pulmonary fibrosis often succumb and live no more than a decade after early onset of breathing problems.Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have developed the HPS-1 proMastocyte (HPM) cell line, containing an HPS-1 mutation. This cell line resembles a progenitor mast cell with reduced granule formation,...
Source: NIH OTT Licensing Opportunities - February 28, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds
This surgical clamp device is particularly useful for intraocular surgeries requiring incision in the sclera. The device provides ease of use for repeated opening and closure of an incision or wound for entry of instruments into the eye. It maintains precise alignment of the wound margins, reducing loss of intraocular fluid and pressure. The NEI seeks licensees or collaborative co-development of this invention so that it can be commercialized.IC: NEINIH Ref. No.: E-293-2016Advantages: Maintains more precise alignment of the wound marginsPermits easy reopening and entry into the incision or wound and repeated...
Source: NIH OTT Licensing Opportunities - February 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds
This surgical clamp device is particularly useful for intraocular surgeries requiring incision in the sclera. The device provides ease of use for repeated opening and closure of an incision or wound for entry of instruments into the eye. It maintains precise alignment of the wound margins, reducing loss of intraocular fluid and pressure. The NEI seeks licensees or collaborative co-development of this invention so that it can be commercialized.IC: NEINIH Ref. No.: E-293-2016Advantages: Maintains more precise alignment of the wound marginsPermits easy reopening and entry into the incision or wound and repeated...
Source: NIH OTT Licensing Opportunities - February 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Tissue Clamp for Repeated Opening and Closure of Incisions/Wounds
Medical clamps currently available are not efficient nor are they sufficiently precise in closure and alignment of the edges of an incision or wound. Many available designs are difficult to use and handle, especially in situations where repeated opening and closure of an incision or wound is required. The functional short-comings of existing clamp designs may result in surgical complications, such as excess loss of fluids and pressure and hemostasis during some procedures. These functional deficiencies may increase the difficulty and expense of a surgery or altogether limit the ability to perform some procedures.This clamp...
Source: NIH OTT Licensing Opportunities - February 21, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Methods for Improving Drug Delivery to the Central Nervous System
The invention relates to the uses of the tricyclic antidepressant amitriptyline, its bioactive metabolites, and other LPA1R activators to improve the bioavailability and delivery of therapeutics to the central nervous system. This invention demonstrates that amitriptyline and other agents selectively decreaseP-glycoprotein (P-gp) transport activity by ligand activation of lysophosphatidic acid 1 receptor (LPA1R) at the blood-brain barrier.P-gp is an effective target for increasing drug delivery to the brain (CNS) for two major reasons: (1) its substrates include a large portion of on-the-market drugs, including chemotherap...
Source: NIH OTT Licensing Opportunities - February 13, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Griffithsin-based Anti-viral Therapeutics with Improved Stability and Solubility
Griffithsin is a potent anti-viral protein with activity against HIV, HCV, Sars, HSV 1& 2 and other viruses. It is active against HIV and HCV at picomolar concentrations. Griffithsin is moving into clinical trials as an anti-HIV microbicide. Based on the structure of griffithsin and the necessities of pharmaceutical product development and regulatory approval, certain mutations in the sequence of griffithsin have been generated which could add to the stability and solubility of the protein. These mutants have all been tested for biological activity, solubility and thermal stability. They possess modified physiological ...
Source: NIH OTT Licensing Opportunities - February 13, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Methods for Improving Drug Delivery to the Central Nervous System
The invention relates to the uses of the tricyclic antidepressant amitriptyline, its bioactive metabolites, and other LPA1R activators to improve the bioavailability and delivery of therapeutics to the central nervous system. This invention demonstrates that amitriptyline and other agents selectively decreaseP-glycoprotein (P-gp) transport activity by ligand activation of lysophosphatidic acid 1 receptor (LPA1R) at the blood-brain barrier.P-gp is an effective target for increasing drug delivery to the brain (CNS) for two major reasons: (1) its substrates include a large portion of on-the-market drugs, including chemotherap...
Source: NIH OTT Licensing Opportunities - February 13, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Anti-PY1235-MET Immunological Binding Reagent as Cancer Diagnostic
This technology consists of highly specific rabbit monoclonal antibodies reactive with phosphorylated tyrosine located at amino acid 1235 in the human MET sequence. Binding to this pYl235 residue is independent of the phosphorylation of other tyrosines in the vicinity (1230 and 1234), does not crossreact with these nearby phosphotyrosine residues, and does not occur when Y1235 is unphosphorylated.The receptor tyrosine kinase MET is an important drug target for treatment of various diseases including diseases mediated by dysregulated cell proliferation (e.g., cancer). A key event involved in MET activation and/or signaling ...
Source: NIH OTT Licensing Opportunities - February 13, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Anti-CD133 Monoclonal Antibodies as Cancer Therapeutics
Most early work on CD133 was carried out using one of two monoclonal antibodies (mAbs), AC133 and AC141, which recognize an undefined glycosylated epitope of CD 133.Researchers from NCI's Pharmacodynamic Assay Development and Implementation Section generated novel anti-human CD133 monoclonal antibodies from large extracellular domain loops of CD133 using peptide residues selected from the native extracellular domains of CD133 protein as an immunogen. They selected sequences for immunization that do not overlap with known glycosylation sites. Peptide antigens comprising the amino acids in the extracellular domain were synth...
Source: NIH OTT Licensing Opportunities - February 13, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Deuterium Magnetic Resonance Imaging (dMRI) for In Vivo Visualization of Rapidly-Dividing Cells
Chronic graft-versus-host disease (cGVHD) is a prevalent and highly lethal condition affecting stem cell transplant recipients. The need for biopsy often delays identification and treatment of cGVHD and other diseases characterized by the presence of rapidly dividing cells, such as cancer. Unfortunately, biopsies are a painful, invasive and slow procedure, which cause discomfort to patients and do not yield rapid results. Because rapid, reliable, and early detection of cGVHD, and other diseases or conditions characterized by the presence of rapidly dividing cells, can improve the long-term prognosis of the patient, there i...
Source: NIH OTT Licensing Opportunities - February 7, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Deuterium Magnetic Resonance Imaging (dMRI) for In Vivo Visualization of Rapidly-Dividing Cells
The National Cancer Institute seeks licensees for a method for in vivo visualization of rapidly-dividing cells and dynamic measurement of cellular kinetics using Deuterium Magnetic Resonance Imaging (dMRI).IC: NCINIH Ref. No.: E-188-2016Advantages: Less invasive alternative to current diagnostic procedures, such as biopsies: decreases patient discomfort.Faster detection method can  improve patient responses to treatment and survival ratesApplications: Non-invasive diagnostic, non-radioactive labeling-imaging approach for many cell types, including neoplastic cells.Development Status: Discovery...
Source: NIH OTT Licensing Opportunities - February 2, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Deuterium Magnetic Resonance Imaging (dMRI) for In Vivo Visualization of Rapidly-Dividing Cells
The National Cancer Institute seeks licensees for a method for in vivo visualization of rapidly-dividing cells and dynamic measurement of cellular kinetics using Deuterium Magnetic Resonance Imaging (dMRI).IC: NCINIH Ref. No.: E-188-2016Advantages: Less invasive alternative to current diagnostic procedures, such as biopsies: decreases patient discomfort.Faster detection method can  improve patient responses to treatment and survival ratesApplications: Non-invasive diagnostic, non-radioactive labeling-imaging approach for many cell types, including neoplastic cells.Development Status: Discovery...
Source: NIH OTT Licensing Opportunities - February 2, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Deuterium Magnetic Resonance Imaging (dMRI) for In Vivo Visualization of Rapidly-Dividing Cells
The National Cancer Institute seeks licensees for a method for in vivo visualization of rapidly-dividing cells and dynamic measurement of cellular kinetics using Deuterium Magnetic Resonance Imaging (dMRI).IC: NCINIH Ref. No.: E-188-2016Advantages: Less invasive alternative to current diagnostic procedures, such as biopsies: decreases patient discomfort.Faster detection method can  improve patient responses to treatment and survival ratesApplications: Non-invasive diagnostic, non-radioactive labeling-imaging approach for many cell types, including neoplastic cells.Development Status: Discovery...
Source: NIH OTT Licensing Opportunities - February 2, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Monoclonal Antibodies that Neutralize Norovirus
Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks.This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies may have application as immunop...
Source: NIH OTT Licensing Opportunities - January 23, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

Monoclonal Antibodies that Neutralize Norovirus
Vaccines and therapies to prevent and treat Norovirus infections do not exist, despite the worldwide prevalence of Norovirus infections. Outbreaks of human gastroenteritis attributable to Norovirus commonly occur in group setting, such as hospitals, nursing homes, schools, dormitories, cruise ships and military barracks.This technology relates to chimpanzee-human chimeric monoclonal antibodies, which specifically bind to Norovirus and have therapeutic potential. The antibodies that were tested in a primate model of infection have shown protection against Norovirus. These Norovirus antibodies may have application as immunop...
Source: NIH OTT Licensing Opportunities - January 23, 2017 Category: Research Authors: ajoyprabhu3 Source Type: research

A Sensitive, High Throughput Pseudovirus-Based Papillomavirus Neutralization Assay for HPV 16 and HPV 18
Human Papilloma Viruses (HPV)  is a very common virus; nearly 80 million people—about one in four—are currently infected in the United States. HPV is a group of more than 150 related viruses. Each HPV virus in this large group is given a number which is called its HPV type. HPV is named for the warts (papillomas) some that HPV types can cause. Some other HPV types can lead to cancer, especially cervical cancer. There are more than 40 HPV types that can infect the genital areas of males and females. Each year, about 38,793 new cases of cancer are found in parts of the body where HPV is often found...
Source: NIH OTT Licensing Opportunities - December 16, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Genetically Engineered Mouse-Derived Allograft for Preclinical Studies of Metastatic Melanoma
The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development.Before testing drugs in humans, drug developers are required to demonstrate a reasonable expectation of safety and efficacy by performing so-called pre-clinical studies.   A key element of such trials is the use of animal models, typically mice or rats that are selected for demonstrating hallmarks of a given disease.  For cancer re...
Source: NIH OTT Licensing Opportunities - November 29, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Genetically Engineered Mouse-Derived Allograft for Use in Preclinical Studies of Metastatic Melanoma Therapies
Before testing drugs in humans, drug developers are required to demonstrate a reasonable expectation of safety and efficacy by performing so-called pre-clinical studies. A key element of such trials is the use of animal models, typically mice or rats that are selected for demonstrating hallmarks of a given disease. For cancer research, while many mouse models exist to simulate the response of the cancer to a particular drug, all of the current models have some limitations in their ability to fully predict the concomitant physiological or immunological response that might result when the drug progresses to clinical trials. ...
Source: NIH OTT Licensing Opportunities - November 29, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines
This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine.IC: NIAIDNIH Ref. No.:&n...
Source: NIH OTT Licensing Opportunities - November 22, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Methods of Making and Using Dopamine D3 Receptor Selective Antagonists/Partial Agonists
Dopamine is a major neurotransmitter in the central nervous system and among other functions is directly related to the rewarding effects of drugs of abuse. Dopamine signaling is mediated by D1, D2, D3, D4 and D5 receptors. The dopamine D3 receptor is a known target to treat a variety of neuropsychiatric disorders, including substance use disorders (e.g., cocaine and opioid), schizophrenia and depression. Despite extensive efforts, it has proven difficult to identify a lead molecule that selectively binds to D3 receptors (versus D2 receptors, for example), with the desired pharmacological and pharmacokinetic profile. For e...
Source: NIH OTT Licensing Opportunities - November 18, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Methods of making and using dopamine receptor selective antagonists/partial agonists
A library of novel compounds that selectively bind the dopamine D3 receptor have been designed and characterized extensively.   In vivo rodent studies indicate selected lead  molecules may be useful to treat drug addiction/dependence.IC: NIDANIH Ref. No.: E-053-2016Advantages: Despite extensive efforts to develop   D3 receptor-selective compounds, it has proven difficult to identify a ligand with the desired pharmacological and pharmacokinetic profile for translation to the clinic.    The D3 receptor ligands described herein may be useful to treat a variety of diseases, including opi...
Source: NIH OTT Licensing Opportunities - November 10, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Methods of making and using dopamine receptor selective antagonists/partial agonists
A library of novel compounds that selectively bind the dopamine D3 receptor have been designed and characterized extensively.   In vivo rodent studies indicate selected lead  molecules may be useful to treat drug addiction/dependence.IC: NIDANIH Ref. No.: E-053-2016Advantages: Despite extensive efforts to develop   D3 receptor-selective compounds, it has proven difficult to identify a ligand with the desired pharmacological and pharmacokinetic profile for translation to the clinic.    The D3 receptor ligands described herein may be useful to treat a variety of diseases, including opi...
Source: NIH OTT Licensing Opportunities - November 10, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Methods of Making and Using Dopamine D3 Receptor Selective Antagonists/Partial Agonists
A library of novel compounds that selectively bind the dopamine D3 receptor have been designed and characterized extensively.   In vivo rodent studies indicate selected lead  molecules may be useful to treat drug addiction/dependence.IC: NIDANIH Ref. No.: E-053-2016Advantages: Despite extensive efforts to develop   D3 receptor-selective compounds, it has proven difficult to identify a ligand with the desired pharmacological and pharmacokinetic profile for translation to the clinic.    The D3 receptor ligands described herein may be useful to treat a variety of diseases, including opi...
Source: NIH OTT Licensing Opportunities - November 10, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Immortalized Stria Vascularis Cell Line SV-k1
Available for nonexclusive licensing for research uses is the cell line, SV-k1, derived from the Organ of Corti. The line was developed from the stria vascularis, an organ localized on the lateral wall of the cochlea, adjacent to the Organ of Corti, containing cell populations specialized in the production of an endolymph very rich in K+ characteristic of the mammalian inner ear. SV-k1 cells express a set of biomarkers completely different of those expressed byOC-k3 cells, and are not sensitive to ototoxic drugs.IC: NIDCDNIH Ref. No.: E-013-2017/0Applications: ResearchHearing researchProvider Technology ID:&...
Source: NIH OTT Licensing Opportunities - November 10, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Immortalized Organ of Corti Cell Line OC-k3
Available for nonexclusive licensing as a research material is a conditionally immortalized Organ of Corti cell line called OC-k3. Sensory cells from the auditory organ, the Organ of Corti, are terminally differentiated and cannot be cultured. Moreover, few of them can be isolated per cochlea and survive only few hours after isolation making impossible to use on them many biochemical and molecular biology techniques. OC-k3, expresses many markers of sensory cells and it has already been used as an in vitro model for a variety of studies.IC: NIDCDNIH Ref. No.: E-012-2017/0Applications: ResearchHearing researc...
Source: NIH OTT Licensing Opportunities - November 7, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Immortalized Organ of Corti Cell Line OC-k3
Available for nonexclusive licensing as a research material is a conditionally immortalized Organ of Corti cell line called OC-k3. Sensory cells from the auditory organ, the Organ of Corti, are terminally differentiated and cannot be cultured. Moreover, few of them can be isolated per cochlea and survive only few hours after isolation making impossible to use on them many biochemical and molecular biology techniques. OC-k3, expresses many markers of sensory cells and it has already been used as an in vitro model for a variety of studies.IC: NIDCDNIH Ref. No.: E-012-2017/0Advantages: MaterialsApplications:&nb...
Source: NIH OTT Licensing Opportunities - November 7, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines
This virus-like particle (VLP) vaccine technology for influenza viruses, based on a mixture of VLPs expressing the hemagglutinin protein or the neuraminidase protein from influenza virus strains belonging to different virus subtypes, has demonstrated broad protection against lethal challenge in mice with various influenza virus strains and virus subtypes. Results from ferret and mouse studies demonstrate broad heterosubtypic protection against various influenza virus subtypes further supporting and strengthening the proposed application of this technology as a universal influenza virus vaccine. This technology is available...
Source: NIH OTT Licensing Opportunities - November 4, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research

A549 Cells: Lung Carcinoma Cell Line for Adenovirus
Scientists at the National Cancer Institute  developed a cell line designated A549 that was derived from explanted cultures of human lung cancer tissue. The A549 cell line has been tested under the guidance of the United States Food and Drug Administration (FDA) so, under current Good Manufacturing Practices (GMP), these cells may be suitabl e for use in manufacturing constructs for use in clinical trials. The A549 cell line has also been found to be suitable for adenovirus production, most notably replicating adenovirus constructs that do not require complementation by the viral oncogene, early region 1A (E1A), which...
Source: NIH OTT Licensing Opportunities - November 2, 2016 Category: Research Authors: ajoyprabhu3 Source Type: research